William Heiden, AMAG
Credibility shredded, AMAG jettisons CEO and 2 drugs as it looks to reorganize around a salvage plan
With its revenue numbers in a tailspin and a top drug under critical review at the FDA following a failed confirmatory study, AMAG …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
